about
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysisCorticosteroids for the long-term treatment in multiple sclerosisNew and emerging immune-targeted drugs for the treatment of multiple sclerosisThe expression of VEGF-A is down regulated in peripheral blood mononuclear cells of patients with secondary progressive multiple sclerosisT-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.Drug therapy for multiple sclerosis.Disease-modifying therapies in relapsing-remitting multiple sclerosis.The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis.Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.Multiple sclerosis: pathogenesis and treatment.Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system?Efficacy and safety of venous angioplasty of the extracranial veins for multiple sclerosis. Brave dreams study (brain venous drainage exploited against multiple sclerosis): study protocol for a randomized controlled trial.Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy.Repeated intrathecal triamcinolone acetonide administration in progressive multiple sclerosis: a review.Long-term treatment risks in multiple sclerosis: risk knowledge and risk perception in a large cohort of mitoxantrone-treated patients.
P2860
Q24202108-EB6F5A1B-BB90-42EF-9572-0F7C893ABB82Q24242150-D96B9666-000A-4AE0-9B4D-263969A80052Q26997067-2A6E3264-BB0E-483B-8744-3F469857A8B3Q28740407-ACD4D3B9-45D3-49F4-8FBA-5EAD672BB8ABQ33723154-BE94DC39-73B5-4D15-A407-426C32FE1B01Q33990246-4FC87AA4-AFAB-4192-9543-4885481B650EQ34122924-1D6F6412-D7E3-4204-B8FC-5DCD20202A82Q34468304-981E1475-475A-412F-8ED8-34239976AA85Q35007948-8752F7C6-F763-41CB-819B-29941AE0AD33Q35151851-5FBF3A25-888D-4CD1-9E72-8D2A44C02256Q35589934-7A0D6103-212E-4C29-AE47-980D41E4A07EQ36432500-A0D094E6-BFBF-4838-BB3A-F6A9B3AE953BQ36597127-815FECD5-0210-4AAF-8227-C814A84CF759Q37590908-73176D8C-7323-40C8-88B4-B2CD2539AA4AQ37957891-C4911336-B472-4721-94E9-79E76210BBA5Q45354300-6824AA06-09AD-42B0-9DF4-4C242B10A554
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Mitoxantrone for multiple sclerosis
@ast
Mitoxantrone for multiple sclerosis
@en
Mitoxantrone for multiple sclerosis
@en-gb
Mitoxantrone for multiple sclerosis
@nl
type
label
Mitoxantrone for multiple sclerosis
@ast
Mitoxantrone for multiple sclerosis
@en
Mitoxantrone for multiple sclerosis
@en-gb
Mitoxantrone for multiple sclerosis
@nl
prefLabel
Mitoxantrone for multiple sclerosis
@ast
Mitoxantrone for multiple sclerosis
@en
Mitoxantrone for multiple sclerosis
@en-gb
Mitoxantrone for multiple sclerosis
@nl
P2093
P2860
P1476
Mitoxantrone for multiple sclerosis
@en
P2093
Filippo Martinelli Boneschi
Marco Rovaris
Ruggero Capra
P2860
P356
10.1002/14651858.CD002127.PUB2
P577
2005-10-19T00:00:00Z